We are live on ! Find out more
FLNA

Filana Therapeutics

103 hedge funds and large institutions have $40.1M invested in Filana Therapeutics in 2025 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 20 increasing their positions, 33 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

183% more call options, than puts

Call options by funds: $4.73M | Put options by funds: $1.67M

81% more capital invested

Capital invested by funds: $22.1M → $40.1M (+$17.9M)

54% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 13

6% more funds holding

Funds holding: 97103 (+6)

3.19% more ownership

Funds ownership: 25.33%28.52% (+3.2%)

39% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 33

Holders
103
Holders Change
+6
Holders Change %
+6.19%
% of All Funds
1.35%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
20
Increased
20
Reduced
33
Closed
13
Calls
$4.73M
Puts
$1.67M
Net Calls
+$3.06M
Net Calls Change
+$2.08M
Name Holding Trade Value Shares
Change
Change in
Stake
ACM
26
ADAR1 Capital Management
Texas
$236K +$186K +81,000 New
Royal Bank of Canada
27
Royal Bank of Canada
Ontario, Canada
$213K -$26.7K -11,592 -14%
GCM
28
Gallacher Capital Management
Colorado
$189K
AWM
29
Apollon Wealth Management
South Carolina
$135K +$7.69K +3,342 +8%
CFM
30
Catalyst Funds Management
Australia
$129K +$59.1K +25,700 +137%
Federated Hermes
31
Federated Hermes
Pennsylvania
$126K +$13.5K +5,875 +16%
LPL Financial
32
LPL Financial
California
$123K +$54.6K +23,747 +129%
American Century Companies
33
American Century Companies
Missouri
$113K +$89.6K +38,961 New
Walleye Trading
34
Walleye Trading
New York
$104K +$37.9K +16,484 +86%
Verition Fund Management
35
Verition Fund Management
Connecticut
$92.1K
Bank of America
36
Bank of America
North Carolina
$82.1K -$2.24K -975 -3%
Osaic Holdings
37
Osaic Holdings
Arizona
$80K -$6.16K -2,679 -7%
Charles Schwab
38
Charles Schwab
California
$75.8K -$550K -239,241 -90%
HT
39
Headlands Technologies
Illinois
$73.6K +$58.1K +25,283 New
Acadian Asset Management
40
Acadian Asset Management
Massachusetts
$71K +$56.2K +24,439 New
Wells Fargo
41
Wells Fargo
California
$57.9K -$8.05K -3,500 -15%
PAS
42
Point72 Asia (Singapore)
Singapore
$50.6K -$39.9K -17,370 -50%
BNP Paribas Financial Markets
43
BNP Paribas Financial Markets
France
$50.1K -$169K -73,691 -81%
Raymond James Financial
44
Raymond James Financial
Florida
$49.4K -$1.93K -837 -5%
Cetera Investment Advisers
45
Cetera Investment Advisers
Illinois
$48.8K +$6.34K +2,758 +20%
BCM
46
Brookstone Capital Management
Illinois
$48.8K -$2.3K -1,000 -6%
MOS
47
MGO One Seven
Ohio
$48.4K -$271 -118 -0.7%
EGM
48
Engineers Gate Manager
New York
$41.7K +$32.9K +14,319 New
Citadel Advisors
49
Citadel Advisors
Florida
$40.3K +$31.9K +13,864 New
ML
50
Mayport LLC
Massachusetts
$39K +$30.8K +13,400 New

FLNA Hedge Fund Activity: Q3 2025 in Review

103 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q3 2025, worth a combined $40.1M — up 81% from $22.1M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new FLNA positions and 13 closed out — a net gain of 7 holders — while 20 added to existing stakes and 33 trimmed.

The largest buyer was Marshall Wace, adding an estimated $4.58M. The largest seller was Charles Schwab, cutting an estimated $550K.

  • 103 institutional investors held Filana Therapeutics (FLNA) as of Q3 2025, up from 97 in Q2 2025.
  • Funds reported $40.1M of Filana Therapeutics stock for Q3 2025, up 81% quarter-over-quarter.
  • 20 funds opened new Filana Therapeutics positions in Q3 2025 and 13 closed out, a net change of +7 holders.
  • The largest Filana Therapeutics buyer in Q3 2025 was Marshall Wace, an estimated $4.58M added.
  • The largest Filana Therapeutics seller in Q3 2025 was Charles Schwab, an estimated $550K sold.

Based on aggregated 13F filings for Q3 2025.